- Home
- MGIH vs NCNA Comparison
MGIH vs NCNA Comparison
Compare MGIH & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- NCNA
- Stock Information
- Founded
- MGIH 1978
- NCNA 1997
- Country
- MGIH Hong Kong
- NCNA United Kingdom
- Employees
- MGIH N/A
- NCNA N/A
- Industry
- MGIH Publishing
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- NCNA Health Care
- Exchange
- MGIH Nasdaq
- NCNA Nasdaq
- Market Cap
- MGIH 18.0M
- NCNA 15.4M
- IPO Year
- MGIH 2023
- NCNA 2017
- Fundamental
- Price
- MGIH $1.61
- NCNA $3.73
- Analyst Decision
- MGIH
- NCNA Buy
- Analyst Count
- MGIH 0
- NCNA 2
- Target Price
- MGIH N/A
- NCNA $5,000.00
- AVG Volume (30 Days)
- MGIH 18.7K
- NCNA 1.1M
- Earning Date
- MGIH 08-26-2025
- NCNA 08-26-2025
- Dividend Yield
- MGIH N/A
- NCNA N/A
- EPS Growth
- MGIH N/A
- NCNA N/A
- EPS
- MGIH N/A
- NCNA N/A
- Revenue
- MGIH $28,866,993.00
- NCNA N/A
- Revenue This Year
- MGIH N/A
- NCNA N/A
- Revenue Next Year
- MGIH N/A
- NCNA N/A
- P/E Ratio
- MGIH N/A
- NCNA N/A
- Revenue Growth
- MGIH N/A
- NCNA N/A
- 52 Week Low
- MGIH $1.34
- NCNA $3.72
- 52 Week High
- MGIH $6.83
- NCNA $2,158.00
- Technical
- Relative Strength Index (RSI)
- MGIH 51.90
- NCNA 29.87
- Support Level
- MGIH $1.53
- NCNA $4.12
- Resistance Level
- MGIH $1.63
- NCNA $5.70
- Average True Range (ATR)
- MGIH 0.06
- NCNA 1.12
- MACD
- MGIH 0.00
- NCNA -0.05
- Stochastic Oscillator
- MGIH 66.67
- NCNA 0.15
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.